Trial Profile
A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Momelotinib (Primary)
- Indications Myelofibrosis
- Focus Biomarker; Therapeutic Use
- Sponsors Gilead Sciences; Sierra Oncology
- 04 Dec 2018 Results assessing blood hepcidin and its corelation with iron availability and erythropoiesis presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 03 Dec 2018 Results presented in the Sierra Oncology media release.
- 03 Dec 2018 According to a Sierra Oncology media release, data from this trial are being presented today at the American Society of Hematology (ASH) Annual Meeting.